Oncternal Therapeutics Inc Stock Price, News & Analysis

Oncternal Therapeutics (Nasdaq: ONCT) announced preclinical data for ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, set to be presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. ONCT-534 aims to address significant unmet needs in treating Castration-Resistant Prostate Cancer (CRPC), particularly against AR splice variant AR-V7. The data, demonstrating anti-tumor activity, may pave the way for ONCT-534 as a next-generation treatment for prostate cancers resistant to current therapies.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced on October 1, 2021, that it has granted equity inducement awards to new employees, including Vice President Emily Samec. The awards include options to purchase a total of 364,900 shares of common stock, with a 10-year term and an exercise price reflecting the closing stock price on the grant date. The options vest over four years, aligning with Nasdaq regulations. Oncternal focuses on innovative oncology therapies, with ongoing clinical trials for candidates like cirmtuzumab and TK216 aimed at addressing significant cancer needs.

Oncternal Therapeutics (Nasdaq: ONCT) and Celularity (Nasdaq: CELU) announced a research collaboration on Sept. 20, 2021, to explore placental-derived cellular therapies targeting ROR1. The partnership will investigate the use of Oncternal's anti-ROR1 monoclonal antibody, cirmtuzumab, alongside Celularity's natural killer cells. Cirmtuzumab has shown potential in reducing tumor cell proliferation in hematological malignancies. Both companies aim to enhance therapeutic strategies for various cancers, leveraging placental-derived cells to overcome current treatment limitations.

Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, will participate in three virtual conferences in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 11:35 am ET, and the Cantor Global Healthcare Conference on September 29 at 11:20 am ET. Webcasts and replays will be available on their investor page.

Oncternal Therapeutics announced the appointment of Steven Hamburger, Ph.D., as Senior Vice President of Regulatory Affairs and Quality Assurance. Dr. Hamburger has over 35 years of experience in drug development, with a focus on oncology and rare diseases. His role is expected to enhance Oncternal's ongoing discussions with the FDA regarding a potential registration study for cirmtuzumab, aimed at treating mantle cell lymphoma. Additionally, inducement awards for stock options were granted to Dr. Hamburger and another new employee to incentivize their joining.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) reported encouraging interim clinical data for cirmtuzumab and TK216 at ASCO 2021. The combination of cirmtuzumab with ibrutinib showed an objective response rate of 83% in heavily pre-treated mantle cell lymphoma (MCL) patients. New treatment cohorts have been added for both MCL and Ewing sarcoma. Financially, Oncternal reported a net loss of $7.7 million for Q2 2021 with $103.7 million in cash, sufficient to support operations into 2023. The management team has been strengthened with new appointments.

Oncternal Therapeutics (Nasdaq: ONCT) announced on August 2, 2021, the granting of inducement awards to two new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The awards include options for a total of 216,400 shares of common stock, with a 10-year term and an exercise price matching the stock's closing price on the grant date. Vesting occurs over four years, beginning with 25% after one year. The compensation committee, composed of independent directors, approved these awards in compliance with Nasdaq regulations.

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT) announced participation in the BTIG Virtual Biotechnology Conference scheduled for August 9-10, 2021. James Breitmeyer, President and CEO, will present a corporate overview on August 9 at 12:00pm (ET) and will be available for one-on-one meetings. Oncternal is focused on developing novel oncology therapies, including cirmtuzumab and TK216, addressing critical cancer treatment needs.

Oncternal Therapeutics (Nasdaq: ONCT) announced it will release its second quarter 2021 financial results on August 5, 2021, post-market. A management webcast will follow at 2:00 p.m. PT to discuss results and provide a business update. The company is advancing oncology therapies addressing unmet medical needs, with a pipeline including cirmtuzumab and TK216, undergoing various clinical trials for cancers such as mantle cell lymphoma and Ewing sarcoma.